Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 47.1% in May

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 13,900 shares, a decline of 47.1% from the May 15th total of 26,300 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average trading volume of 24,200 shares, the short-interest ratio is currently 0.6 days.

Analyst Ratings Changes

A number of research analysts have issued reports on ASMB shares. Guggenheim assumed coverage on Assembly Biosciences in a research report on Tuesday, March 25th. They issued a "buy" rating and a $31.00 target price on the stock. Wall Street Zen cut Assembly Biosciences from a "buy" rating to a "hold" rating in a report on Monday, March 24th. Finally, HC Wainwright restated a "neutral" rating on shares of Assembly Biosciences in a report on Monday, March 24th.

Institutional Trading of Assembly Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Palumbo Wealth Management LLC bought a new stake in Assembly Biosciences in the fourth quarter valued at approximately $180,000. JPMorgan Chase & Co. boosted its holdings in Assembly Biosciences by 225.6% in the fourth quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company's stock valued at $180,000 after acquiring an additional 7,918 shares during the last quarter. American Century Companies Inc. bought a new stake in Assembly Biosciences in the first quarter valued at approximately $113,000. Marshall Wace LLP boosted its holdings in Assembly Biosciences by 16.5% in the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 2,098 shares during the last quarter. Finally, Man Group plc bought a new stake in Assembly Biosciences in the fourth quarter valued at approximately $309,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Trading Down 1.5%

NASDAQ:ASMB opened at $16.85 on Friday. The stock has a market cap of $128.70 million, a P/E ratio of -2.70 and a beta of 0.55. The stock's 50-day moving average is $12.64 and its 200-day moving average is $13.23. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $19.93.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($2.01) by $0.84. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The company had revenue of $9.42 million for the quarter, compared to analysts' expectations of $7.41 million. As a group, equities analysts forecast that Assembly Biosciences will post -6.87 EPS for the current year.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.